Set Study Preferences

This study management action enables you to globally set custom study-level attributes, subject-level preferences, analysis preferences for each CDISC class of reports, preferences for calculating study days, as well as preferences for advanced operations. A subset of these study-level preferences are also available on individual reports and are used as initial values for report options, but can be overridden in reports either through review templates or interactively. Some categories in this dialog are only available if they are applicable to the study data.

Click

to expand each section and specify preferences.

Note: Some Report categories are surfaced only when the selected study meets the requirements for the reports in that category. As a result, you may not see all of the categories shown below for your study.

Custom Study Attributes

Options shown in this category are determined by the Manage Configurations > System Preferences > Study Management > Custom Study Attributes specification, so this category will be shown only if at least one custom study attribute key has been defined. All studies for a given configuration will display the same set of custom study attributes in the Set Study Preferences dialog. These attributes are displayed on the study information panel of study selector windows, and always appear at the top of the panel.

The Indication and Description options are shown by default. This is a place for the user to enter descriptive text regarding the study

Indication

The Indication is simply a short phrase about what the study’s general focus is, or the presumptive use for the drug being investigated.

Description

The Description is longer and more open-ended than the Indication. Use this field to expand on any details about the study that you may feel relevant to reviewers or others users.

Subject Level Preferences

This category includes treatment variable, treatment control value, demographic grouping, and analysis population choices, among others. Some of these preferences are not available on individual reports.

Note: JMP Clinical automatically tries to assign default values for each of the subject level preferences based on flags found in the ADSL, ADDM, or DM (and optionally SUPPDM) data sets as well as prior selections. Use the individual widgets to modify the selections.

Treatment Variable

Use the Treatment Variable widget to specify the variable defining the actual or planned treatment used in the study. Available variables might include either a planned treatment , which is selected when the treatments patients received exactly match what was planned the variable specifying the actual treatmentActual, which is selected when treatment deviates from what was planned. You can also specify any demographic variable from DM and/or ADSL as a surrogate for the treatment variables.

Treatment Control Level

Use this widget to specify the term used in the Treatment variable to specify the study's control. The Treatment Control Level is specified as either “Placebo” or “Pbo”, depending on the value found in your data, by default.

Crossover

Use this widget to indicate that your study contains crossover data.

Demographic Grouping

Use this widget to specify the Demographic Grouping to use for segregating the results of your analysis.

Select the analysis population

This list is populated with available populations that can be defined for the current Study based on flags found in the ADSL, ADDM, or DM (and optionally SUPPDM) data sets. Use the drop-down menu to select the set of individuals to include in the analysis.

Set Age Groups

Check the Set Age Groups check box if you want to group study subjects by age.

Perform treatment comparison analysis for demographic variables.

Check this box to generate the treatment comparisons among the selected demographic variables.

Create additional distributions for selected variables

This option enables you to add or remove demographic variables from DM from the distributions.

Click

to open the Add window shown below:

Select one or more variables and click .

To remove one or more distributions, highlight the variables to be deleted and click

To rearrange the order of the distributions, select a variable and click either

By Variables

BY variables are optional (in most reports) variable specifications whose values define groups of observations, such as hour, month, or year. BY variables can enable analyses to be performed separately on different groups as defined by that variable. Choosing a BY variable such as gender (ADSL variable = SEX), for example, groups the subjects by gender and conducts two separate analyses: one for males and one for females.

Alternatively, specifying a BY variable enables you to animate an image so that you can see how response values change according to some grouping over time.

Click

to open the Add window (shown below) that lists each variable contained in domain and SUPPxx (if merged) specific to this report

Note: In Demographics Distribution only, variables are taken from ADSL, in addition to the report-specific DS and SUPPPDS (if available) data sets.

Select the variables that you want to include in the analysis and click to add those variables to the text box.

In this example, AGE, RACE, and SEX were selected and added.

Note: If no BY variables are specified, the analysis is conducted across all the subjects

Adverse Events

This category is available if the study contains an adverse events data set.

Ignore available treatment emergent flags

If you choose to Ignore available treatment emergent flags, the analysis includes all adverse events that occur on or after day 1 of the study.

Offset for End of Dosing

By default, post-treatment monitoring begins after the patient receives the last treatment. However, you might want to specify an Offset for End of Dosing, increasing the time between the end of dosing and post-treatment monitoring for treatments having an extended half-life.

Include serious adverse events only

Check the Include serious adverse events only check box to include only serious adverse events in the analysis. Serious events are identified by a “Y” value in the expected AESER variable in AE or ADAE.

Event Type

Analysis can consider all events or only those that emerge at specific times before, during, or after the trial period. For example, selecting On treatment events as the Event Type includes only those events that occur on or after the first dose of study drug and at or before the last dose of drug (+ the offset for end of dosing).

Term Level

Use the Term Level widget to specify which level of terms to use as categories.

Term and Group Level

Term and Group Levels are determined by the coding dictionary for the Event or Intervention domain of interest, typically these levels follow the MedDRA dictionary. You must indicate how each adverse event is named and the level at which the event is considered. For example, selecting Reported Term for the Adverse Event, grouped by Body System or Organ Class reports the event specified by the actual event term as reported in the AE domain on the affected organ or body system.

Stack

Use the Stack widget to distinguish different levels within each of the adverse events summarized on the same the bar in the plots.

Time at Risk

Use the Time at Risk: widget to specify how to calculate each patient's duration in patient years. If the Time at Risk is calculated from specified patient time at risk and event flag variables, then it is assumed that the variables that you select appropriately match the selection on this dialog for clear communication of results on the report output.

Patient Years Multiplier

The selection of the incidence rate multiplier can be dependent on the number of subjects in a study and the cumulative time on study/treatment. Use the Patient Years Multiplier: widget to select a multiplier for incidence rates for better interpretability and comparison among studies.

Determine Time at Risk and Adverse Event Inclusion from:

Use the Determine Time at Risk and Adverse Event inclusion from: widget to specify whether JMP Clinical should calculate patient years and event inclusion based on study date variables or from derived patient years/time at risk and event inclusion flags.

Offset (in Days) to Include with End Date Variable

Use the Offset (in Days) to Include with End Date Variable widget to specify the number of days after the last date of study or exposure for calculation of patient time at risk and adverse event variable inclusion.

Date for Ongoing Subjects

Use the Date for Ongoing Subjects widget to specify an end date for subjects that are continuing in the clinical trial.

Medical Query Type

Use the Medical Query Type widget to specify whether the medical queries are FDA Medical Queries (FMQs) or Standardized MedDRA Queries (SMQs).

Version of FDA Medical Query Files/Version of Standardized Medical Query Files

Use this widget to specify the version of the Medical Query files to use in the analysis. Options include all of the Medical Query files stored in the Medical Query directory specified for your configuration. Refer to General File Paths for information about the location of this directory. This option is dependent on the medical query type specified above.

Italicize medical query terms

Check this box to italicize the medical query terms in the reports.

Adverse Events Narrative

AE Narrative Template

Use the AE Narrative Template option to select the template for the narrative. Templates enable you to customize the narrative in a variety of layouts and/or styles. The templates are read by JMP Clinical at run time and available for selection when creating the final document. The result of this design enables very customizable output that can be altered and/or extended as appropriate for different types of studies or specific regulatory requests.

Sort by narrative category

Check the Sort by narrative category option to sort the narrative by category of fatal adverse events, serious adverse events, adverse events leading to discontinuation, or adverse events of special interest.

Include subject level table of contents

Check this box to Include subject-level table of contents in the narrative.

Use Subject Identifier for study in lieu of Unique Subject Identifier

The Use Subject Identifier for study in lieu of Unique Subject Identifier widget enables you to use the subject identifier for study (SUBJID), if it is available, in lieu of unique subject identifier (USUBJID) in the narrative text. If SUBJID is not available, USUBJID is used as normal.

Adverse Events Categories

Use the drop-down menu to specify the category of adverse events to include in the narrative. Options include fatal serious adverse events only, serious adverse events only, non-serious adverse events leading to discontinuation, or all adverse events.

Number of Days Around Adverse Event Start Date for Reported Related Events

You might want to include in the narrative additional events that occur at or about the same time as the reported adverse events. Use the Number of days around Adverse Event start date for reported related events option to specify the number of days before and after the onset of the adverse event, within which the additional events are considered. only those events falling within the specified time are included in the narrative.

Limit reported related events to those that are serious

By default, reporting additional adverse events that occur close in time to each summarized event includes all adverse events experienced by the patient. Use the Limit reported related events to those that are serious option limit those events to serious adverse events only.

Include the reported event term in the header only when different than the coded term

Both the coded term for the AE (AEDECOD) and the reported term are included in the headers within the narrative. You can use the Include the reported event term in the header only when different than the coded term to include the reported event term (AETERM) in the header only when different from the coded term (AEDECOD). If they are the same, only the coded term is used.

Include Exposure (EX) in the narrative

You can opt to Include Exposure (EX) in the narrative. The report sums up values of EXDOSE for each day across all records. It does not take into account units such as mg/hr or dosing frequency such as BD or QD. Instead, this report takes the simplest possible approach and assumes that the study sponsors would ultimately report the total dose for a particular study day in EXDOSE. This is also partially why including dosing into the narrative is optional.

All study treatments are to be taken at least once per day

If the study protocol that all study treatments are to be taken at least once each day you should check the All study treatments are to be taken at least once per day option. This is used to calculate drug (including dose interruptions) dosage at the time of the event. Note: This option is checked by default. You should uncheck this box if at least one drug is taken less frequently than once per day.

A 0 dose for placebo or vehicle indicates a dose interuption

The A 0 dose for placebo or vehicle indicates a dose interruption option is used when a dose of 0 for either the placebo or the treatment indicates a dose interruption. This option is specified by default.

Include a summary table of concomitant medications

Use this widget to report information about the concomitant medications study subjects are taking and their possible relationship to observed adverse effects. Note: By default, concomitant medications are not summarized in the narrative. Use the Include a summary table of concomitant medications to include this information.

Use original study days instead of derive values

When you opt to include a summary table of concomitant medications, you can also opt to Use original study days instead of derived values

Number of Days Prior to Adverse Event Start Date for Reporting Concomitant Medications

The Number of days prior to Adverse Event start date for reporting concomitant medications option enables you to specify the time period on or before treatment that you want to consider. A value of 0 indicates medications that were taken the day of event onset; this value is specified by default. A value of X includes concomitant medications that were taken on the day of the onset of the AE and up to X days prior to AE onset.

Concomitant Medications are reported in text using:

Use the Concomitant medications are reported in text using: option to specify how to report the name of the drug.

Include concomitant medication indication in narrative text

Check this box to include a table concomitant medication indications in the narrative.

Medical history terms are summarized as a:

You can specify whether the Medical history terms are summarized as a table or a list.

Medical history terms are reported using:

Use the Medical history terms are reported using: widget to specify the appropriate medical history terms to be used in narrative text.

Include a findings domain in the narrative

You can opt to Include a findings domain in the narrative.

Include a summary of baseline findings

You might opt to Include summary of baseline findings in the narrative. Note: If the Laboratory Test Results (LB) domain has been specified, only abnormal baseline lab tests are summarized in the body of the narrative.

Include closest on-study findings test dates

Use the Include closest on-study findings test dates: option to specify whether to report results from lab tests taken prior to or on the day of the onset of the adverse event only, results of tests taken subsequent to the onset of the adverse event only, results from tests taken both before and after the onset. You can also choose Neither to include none of the lab results.

Include on-study lab tests where reference range indicator is:

Use the Include on-study lab tests where reference range indicator is: option to specify which findings results to include in the narrative.

Refer to findings tests using

Use the Refer to findings tests using: option to specify the terminology used to refer to the findings results in the narrative.

Other Events

This category is available if the study contains at least one events data set aside from adverse events.

Ignore available treatment emergent flags

If you choose to Ignore available treatment emergent flags, the analysis includes all events that occur on or after day 1 of the study.

Offset for End of Dosing

Define events as:

Use this widget to specify those discontinuations that are to be considered as events. This option is used for records where the value in DSCAT is Disposition Event.and the last one (sorting by DSSTDTC) is selected (unless a where statement is defined to choose the records, 1 per person). Refer to Define events as: for more information.

Domain

Use the Domain option to specify whether to analyze either disposition (DS) or medical history (MH) events.

Event Type

Term Level

Use the Term Level widget to specify which level of terms to use as categories.

Term and Group Level

Stack

Use the Stack widget to distinguish different levels within each of the events summarized on the same the bar in the plots.

Clinical Events

This category is available within Other Events if the study contains a clinical events data set.

Ignore available treatment emergent flags

If you choose to Ignore available treatment emergent flags, the analysis includes all adverse events that occur on or after day 1 of the study.

Offset for End of Dosing

Event Type

Term Level

Use the Term Level widget to specify which level of terms to use as categories.

Term and Group Level

Interventions

This category is available if the study contains at least one interventions data set.

Ignore available treatment emergent flags

If you choose to Ignore available treatment emergent flags, the analysis includes all interventions that occur on or after day 1 of the study.

Offset for End of Dosing

Domain

Use the Domain option to specify whether to analyze either concomitant medication (CM) or exposure (EX) interventions.

Intervention Type

Analysis can consider all events or only those that emerge at specific times before, during, or after the trial period. For example, selecting On treatment interventions as the Intervention Type includes only those interventions that occur on or after the first dose of study drug and at or before the last dose of drug (+ the offset for end of dosing).

Term Level

Use the Term Level widget to specify which level of terms to use as categories.

Term and Group Level

Term and Group Levels are chosen from available variables in the Intervention domain of interest. You must indicate how each intervention is named and the level at which the intervention is considered. For example, selecting Standardized Medication Name, grouped by Category for Medication as the Term Level and Group Level, respectively, reports the intervention within the Medication Category as provided in the CM domain.

Stack

Use the Stack widget to distinguish different levels within each of the events summarized on the same the bar in the plots.

Findings

This category is available if the study contains at least one findings data set.

Plot findings measurements as:

Use the Plot findings measurements as: widget to select the type of findings measurement values to plot.

Calculate baseline as:

Use this widget to specify how the baseline findings measurements should be calculated. Refer to Calculate baseline as: for more information.

Summary Statistic for Trial Data

Select the statistic used to summarize the data from the trial period. Refer to Summary Statistic for Trial Data for information about each of the options.

log Transformation of Lab Measurements

Use the drop-down menu to select the transformation to be applied to the baseline and experimental measurements. Refer to log Transformation of Lab Measurements for more information about available transformations.

Lab Test Short Name for Bilirubin

Use this text field to specify the Test Short Name (LBTESTCD) value that corresponds to the bilirubin test. By default, attempts to detect common recommended values for the bilirubin test. If it finds one, the report automatically enters it in the text box. If an alternative designation is used in your study, the field is left blank and you must specify the designation. Refer to Lab Test Short Name for Bilirubin for more information.

Click

to open the Add window (shown below) that that lists available test names (shown below).

Select the short name for bilirubin and click to add it to the text box.

Lab Test Short Name for Alanine Aminotransferase

Use this widget to specify the Test Short Name (LBTESTCD) value that corresponds to the alanine aminotransferase test, as described for bilirubin. Refer to Lab Test Short Name for Alanine Aminotransferase for more information.

Lab Test Short Name for Aspartate Aminotransferase

Use this widget to specify the Test Short Name (LBTESTCD) value that corresponds to the aspartate aminotransferase test, as described for bilirubin. Refer to Lab Test Short Name for Aspartate Aminotransferase for more information.

Lab Test Short Name for Alkaline Phosphatase

Use this text field to specify the Test Short Name (LBTESTCD) value that corresponds to the alkaline phosphatase test, as described for bilirubin. Refer to Lab Test Short Name for Alkaline Phosphatase for more information.

Lab Test Short Name for Gamma-Glutamyl Transferase

Use this text field to specify the Test Short Name (LBTESTCD) value that corresponds to the gamma-glutamyl test, as described for bilirubin. Refer to Lab Test Short Name for Gamma-Glutamyl Transferase for more information.

Lab Test Short Name for International Normalized Ratio

Use this text field to specify the Test Short Name (LBTESTCD) value that corresponds to the INR test, as described for bilirubin. Refer to Lab Test Short Name for International Normalized Ratio for more information.

Lab Test Short Name for Creatinine

Use this text field to specify the Test Short Name (LBTESTCD) value that corresponds to the creatinine test, as described for bilirubin. Refer to Lab Test Short Name for Creatinine for more information.

Lab Test Short Name for Glomeruler Filtration Rate

Use this text field to specify the Test Short Name (LBTESTCD) value that corresponds to the glomerular filtration rate test, as described for bilirubin. Refer to Lab Test Short Name for Glomerular Filtration Rate for more information.

Lab Test Short Name for Cystatin C

Use this text field to specify the Test Short Name (LBTESTCD) value that corresponds to the Cystatin C test, as described for bilirubin. Refer to Lab Test Short Name for Cystatin C for more information.

Additional Lab Test Short Name

Use this text field to specify the Test Short Name (LBTESTCD) value that corresponds toan additional test that ou want to include, as described for bilirubin. Refer to Additional Lab Test Short Name for more information.

Time Lag (in Days) for Classifying Hy's Law Cases

Use the widget to specify a lag time for classifying a subject as a Hy's Law case. Refer to Time Lag (in Days) for Classifying Hy’s Law Cases for more information.

Normalize laboratory values by:

Use this widget to select the reference values to use for performing Hy's Law Screening. Refer to Normalize laboratory values by: for more information.

Only include on-trial measurements

Use this option to filter the laboratory domain records to consider only measurements that are taken after Study Day 1 and are not flagged as baseline. This option is applicable only when you normalize laboratory values by the Upper Limit of Normal. This option does not apply when normalizing by Baseline. Refer to Only include on-trial measurements for more information.

Label Hy's Law quadrants

Check the box to annotate the plot of Bilirubin against Alanine Aminotransferase with terms relating to Hy’s Law. Refer to Lab Test Short Name for Alkaline Phosphatase for more information.

Set custom reference lines for Hy's Law plots

Check this option to use a custom threshold for drawing reference lines for Bilirubin (on the X axis) and for Alanine Aminotransferase (on the Y axis) of the plot. When this box is checked, you can change the values that you want to draw reference lines using the Set reference line for bilirubin and Set reference line for transaminase tests options. If left unchecked, traditional Hy’s Law reference lines (twice the upper limit of normal (ULN) for bilirubin and three times the ULN for alanine aminotransferase) are drawn.

Set reference line for bilirubin

Use this widget to specify a custom reference line for the bilirubin test (BILI) to be drawn on the Hy’s Law plot.

Set reference line for transaminase tests

Use this widget to specify a custom reference line for the alanine transaminase test (ALT) and aspartate transaminase test (AST) to be drawn on the Hy’s Law plot. This same custom threshold is used for both ALT and AST.

Set reference line for alkaline phosphatase

Use this widget to specify a custom reference line for the alkaline phosphatase test (ALP) to be drawn on the Hy’s Law plot.

Summarize sites with at least this many subjects:

Use the Summarize sites with at least this many subjects: widget to specify the number of subjects a site must have in the selected population in order to include it in the summary

Ignore duplicate records within subject

Check the Ignore duplicate records within subject check box to delete multiple occurrences of the same subject within each set of duplicate records. If a set of duplicates is based entirely on one subject, these sets are removed.

Remove tests when percentage of subjects expected for a test is equal to or below:

Use the Remove tests when percentage of subjects expected for a test is equal to or below: widget to specify a threshold level for participating in a test. Tests in which the percentage of subjects receiving that test falls below the set threshold are excluded from the analysis. This option is useful from excluding tests that are conducted only rarely from the analysis. If a test is rare or unexpected at a visit or time point, this option prevents it showing up as missing for the populations of subjects under analysis.

Alpha

Alpha is the false positive or false discovery rate that you desire across all of the hypothesis tests. Alpha must be a real number between 0 and 1; it is typically set at either 0.01, 0.05 or 0.10.

Match subjects based on:

Select either Birthday or Initials to use as criteria for matching subjects. Refer to Match subjects based on: for more information.

Number of Days Around Birthday

Use this widget to specify the number of days around a given birthday to consider as a match. Refer to Number of Days around Birthday for more information.

Consider the following criteria when matching

Use this widget to specify the demographic variable(s) to consider as criteria when determining matching. Options include Sex, Race, and Ethnicity.

Domain

Use the Findings Domain to Analyze option to specify whether to plot the distribution of measurements from either the Electrocardiogram (EG), Laboratory (LB), or Vital Signs (VS) findings domains.

Findings Tests

Use this widget to select specific Findings tests.

Click

to open the Add window (shown below) that lists available test names (shown below).

Select the desired test(s) and click to add them to the text box.

Oncology

This category is available if the study contains at least one oncology-related data set (e.g., RS, TR, TS, TU).

Disease Response Swimmer Plot

Disease Response Test for Analysis

Use the Disease Response Test for Analysis widget to select the relevant test code (RSTESTCD) whose results (RSSTRESC) contain values for tracking response assessment of Complete Response, Partial Response, Progressive Disease, or Stable Disease across study visits/time points. By default, if this option is left blank the report will attempt to find and use an RSTEST value of OVERALL RESPONSE (case insensitive).

Category for Response Assessment Criteria Identification

Use the Category for Response Assessment Criteria Identification widget to filter/select to the specific response assessment criteria value to use for showing response assessment in the resulting swimmer plot and table. If this field is left blank or your data does not contain the expected variable RSCAT with valid values of criteria identification, all records will be considered for the given selected test or algorithmically for any test named OVERALL RESPONSE.

Calculate Overall Response Rate as:

Use the Calculate Overall Response Rate as to select the option for which to calculate Response Rate Summaries displayed in the table for each subject. Choose Best to select a representative response that indicates the best response a patient had recorded at any time during response assessment using preferential logic of CR, PR, SD, PD order. Choose Last to take the last response assessment recorded for each subject. Note: If multiple responses are observed at the final visit, the best among them is reported.

Start Date to Use for Subject Duration / End Date to Use for Subject Duration

You must specify the start and end dates for collecting data to assess response of patients to the treatments. The Start Date to Use for Subject Durationand End Date to Use for Subject Duration widgets are used to select which variable date reference from the demography domain to use for calculating the response duration.

Show lines connecting responses

Checking the Show lines connecting the responses widget connects the observations with lines.

Display subject identifiers on swimmer plot y-axis

By default, subject identifiers are not included on the swimmer plots. Click the Display subject identifiers on swimmer plot y-axis box to display the subject identifiers on the y-axes of the plots.

Include all subjects in swimmer plot regardless of disease response assessment results

You can include all subjects, regardless of disease response by checking the Include all subjects in swimmer plot regardless of disease response assessment results widget.

Include Stable Disease responses on swimmer plot

By default, stable disease responses are not included on the swimmer plots. You can include these responses by checking the Include Stable Disease responses on swimmer plot widget.

Include Progressive Disease responses on swimmer plot

By default, progressive disease responses are not included on the swimmer plots. You can include these responses by checking the Include Progressive Disease responses on swimmer plot widget.

Group Subjects by Treatment Variable

Swimmer plots are presented in order of longest to shortest time subjects have participated in the study, irrespective of treatment. The Group Subjects by Treatment Variable option enables you to group and color-code subjects by treatment.

Use Grey Scale for Bar Color

You can opt to display the bars and response markers on the swimmer plot in grey scale by checking the Use Grey Scale for Bar Color widget.

Progression Free Survival

End Date Variable to Use for Censoring

For patients who survive progression-free beyond the end of the study, the ultimate progression-free survival values for these individuals are unknown. All that can be said is that progression-free survival exceeds the period of the study; these data are considered censored. For these cases, you must specify the end date for collecting data to assess progression. The End Date Variable to Use for Censoring widget is used to select which variable date reference from the demography domain to use for calculating the censored disease progression values. Patients who progress after this date are not considered as progressing. The Last Response Assessment Date is chosen by default.

Offset for Censor End Date (in Study Days)

The Offset for Censor End Date (in Study Days) option enables you to specify a minimum time interval following censor end date that can be used to determine whether progression has occurred. Patient who progress within that threshold are considered to have progressed whereas patients who progress after the specified threshold are not.

Type of Analysis

The Type of Analysis widget enables you to specify whether you want to measure Progression Free Survival or Time to Progression. Progression free survival measures the time from patient randomization to either tumor progression or death. Time to progression censors death and only considers objective tumor progression. A note is added to the top of the report indication which type of analysis has been selected.

Advanced

Options in this category affect wide-ranging aspects of system and report behavior that are not specific to a domain class. These include column, display, sort, adjunct data path, definition, and scale preferences, among others.

Preserve all input data set columns in reports

Check this box to include all input data columns in the output data table, rather than just the data in the required columns.

Snapshot Records to Include

Use this widget to specify which updated snapshot records to include in your analysis.

Number of Decimals to Display for Numeric Results

Use this option to specify the number of decimals to include in the plots and tables of numerical results.

Remove unscheduled visits

Check this option to remove unscheduled visits from the analysis. For a given Findings domain, any record where the VISIT variable (if it exists) contains unscheduled (case insensitive) is removed from the analysis.

Sort Distribution Report table by:

Use the Sort Distribution Report table by: widget to specify how the rows in the distribution reports table are to be sorted.

Sort Risk Report plot and tables by:

Use the Sort Risk Report plot and tables by: widget to specify how the rows in the Risk Report plot and tables are to be sorted.

Treatment Value for Sort by:

Use this widget to specify the treatment value to sort the plots and tables by. This is especially useful when there are multiple treatment regimes. Refer to Treatment Value for Sort by for more information.

Risk Measurement

Use the Risk Measurement drop-down menu to specify the risk measurement to use.

Display Risk Difference as:

Use this widget to specify the difference between the risk of an event in the treatment arm and the control arm as either a percentage or a proportion of the total subject population. This widget appears only when you select Risk Difference as the Risk Measurement.

End Date Variable to Use for Censoring

Use the End Date Variable to Use for Censoring option for specifying the end date for censoring. Options include the reference end date, date of the last treatment, the date on which the subject left the study or the date of the last disposition record (selected by default).

Offset for Censor End Date (in Study Days)

Use this widget to specify the number of days to extend your analysis after the date specified using the End Date Variable for Censoring option.

Use data cutoff date for ongoing subjects

Check this box to use the date on which the study data was pulled for this report in place of exposure end date for ongoing subjects.

Data Cutoff Date

Use this option to specify the date on which the study data was pulled for this report. Refer to Data Cutoff Date for more information.

Count randomized subjects with no disposition event as ongoing

Check this box to count subjects who do not have a record in DS for either Completed or Discontinued as Ongoing for treatment and study status.

A 0 dose for placebo or vehicle indicates a dose interruption

Check this box if a dose of 0 for either the placebo or the vehicle indicates a dose interruption. When this box is unchecked, 0 doses is interpreted as a period where placebo or vehicle was given.

Show Counts for Missing Values

Check the box to add a row to summary statistics for the count of missing values.

Time Scale

Use this widget to specify the time scale to use for times. Options include Days, Weeks, Months, and Years. Refer to Time Scale for more information

Action Buttons

Click to revert all study preferences to their default values.

Click to apply all changes to the study preferences.

Click to reject all changes and return study preferences to the previously saved state.

Tips

Category disclosure states are saved, so Reset, OK, and Cancel apply to those states as well.

To view or edit multiple studies' preferences simultaneously, select at least two studies and click Set Study Preferences. This might be useful if a configuration-wide reset of study preferences is desired.

Where possible, study preferences propagate through study management operations (e.g., Refresh Study Metadata, Update Study with New Snapshot) or are otherwise updated to applicable defaults.